Mortality in the ETO cohort (n = 18 235*)
| Cause (ICD-9 code) | Observed deaths | SMR (95% CI) | Male SMR (95% CI) | Female SMR (95% CI) |
|---|---|---|---|---|
| *These analyses include the entire cohort. Subsequent exposure-response analyses are based on a reduced cohort in which one small plant (4% of cohort) without adequate exposure data was not included. | ||||
| All causes | 2852 | 0.90 (0.88–0.93) | 0.94 (0.89–0.99) | 0.86 (0.81–0.91) |
| Coronary heart disease (410–414) | 669 | 0.92 (0.86–0.98) | 1.04 (0.85–1.04) | 0.87 (0.78–0.99) |
| All cancers (140–208) | 860 | 0.98 (0.92–1.03) | 0.94 (0.95–1.16) | 0.92 (0.84–1.01) |
| Stomach (151) | 25 | 1.07 (0.74–1.49) | 0.87 (0.44–1.52) | 1.34 (0.71–2.29) |
| Pancreas (157) | 38 | 0.92 (0.69–1.21) | 1.03 (0.64–1.61) | 0.82 (0.45–1.30) |
| Lung (162) | 258 | 1.05 (0.95–1.17) | 1.05 (0.89–1.23) | 1.05 (0.86–1.27) |
| Prostate (185) | 37 | 1.29 (0.91–1.78) | 1.29 (0.91–1.78) | n.a. |
| Kidney (189.0–189.2) | 21 | 1.19 (0.80–1.72) | 1.51 (0.85–2.49) | 0.78 (0.281.28) |
| Brain (191–192) | 14 | 0.59 (0.36–0.91) | 0.52 (0.19–1.13) | 0.65 (0.25–7.37) |
| Bone (170) | 6 | 2.82 (1.23–5.56) | 3.51 (0.96–8.98) | 2.04 (0.25–7.37) |
| Breast cancer (174) | 103 | 0.99 (0.84–1.17) | 2.04 (0.05–11.37) | 0.99 (0.81–1.20) |
| All haematopoietic (200–208) | 79 | 1.00 (0.79–1.24) | 1.09 (0.79–1.47) | 0.91 (0.84–1.25) |
| Non-Hodgkin’s lymphoma (200, 202) | 31 | 1.00 (0.72–1.35) | 1.29 (0.78–2.01) | 0.73 (0.38–1.29) |
| Hodgkin’s disease (201) | 6 | 1.24 (0.53–2.43) | 1.83 (0.59–4.27) | 0.47 (0.05–11.87) |
| Myeloma (203) | 13 | 0.92 (0.54–0.87) | 0.61 (0.17–1.56) | 1.19 (0.54–2.26) |
| Leukaemia (204–208) | 29 | 0.99 (0.71–1.36) | 0.97 (0.52–1.63) | 1.02 (0.57–1.68) |